Brutalist Biotech

• Roche's Genentech sticks with Orionis in 2nd molecular glue deal worth $2B (1h)
• Accropeutics' TYK2/JAK1 inhibitor hits psoriasis endpoints in Chinese biotech's first phase 2 win (4h)
• PureTech shows durability of pulmonary fibrosis candidate deupirfenidone (19h)
• Schrödinger lays off 60 staffers amid ‘uncertain times and challenging economic conditions’ (21h)
• BioNTech pledges £1B to bolster UK presence while nabbing £129M grant from government (22h)
• Blueprint changes up $1.67B VantAI pact again, zeroing in on molecular glue potential (22h)
• SV Health’s latest pharma-backed dementia fund raises $269M to invest in new therapies (23h)
• RegenXBio cashes in $250M worth of payments for Zolgensma, 2 other gene therapies (1d)
• Pfizer pays 3SBio $1.25B for PD-1xVEGF bispecific, joining red-hot race with BioNTech, Merck (1d)
• Stars align for CRISPR Tx, Sirius as pair pen siRNA collab with a focus on thrombotic disease (1d)

• FDA sets stricter approval standards for COVID vaccines (20h)
• Tourmaline shares fall on Phase 2 data; Schrödinger cuts staff (22h)
• Pfizer buys into PD-1/VEGF competition with 3SBio deal (23h)
• Prime Medicine claims ‘proof of concept,’ but lays off staff in pivot (1d)
• Novavax’s COVID vaccine gets FDA approval, but with limits (1d)
• Regeneron wins bid to buy 23andMe out of bankruptcy (2d)
• FDA OKs first blood test to aid Alzheimer’s diagnosis (2d)
• How regulatory convergence is raising the bar for sterile drug safety—and how West leads the way (2d)
• From insight to impact: How eCOAs strengthen trial data quality (2d)
• Bridging the data gaps that impact retail and specialty-lite success (2d)

• Genentech expands partnership with molecular glue biotech Orionis (2h)
• How PureTech’s lung fibrosis drug stacks up against the competition (2h)
• Altos Labs buys anti-aging startup Dorian Therapeutics (4h)
• Reproductive health biotech ReproNovo closes $65M Series A (5h)
• UK biotech Juvenescence targets $150M+ for 'healthy lifespan' drug candidates (7h)
• Vinay Prasad makes first major imprint on FDA with new vaccine policy (16h)
• FDA adcomm votes against new indication for Genentech's cancer drug (17h)
• CRISPR Therapeutics partners with siRNA company, showing that gene editing isn’t the only answer (18h)
• RFK Jr. spars with senators over HHS budget and research cuts (19h)
• Future Covid vaccine approvals may narrow to older adults, high-risk people (22h)

• RFK Claims Ignorance About HHS Research, Clinical Trial Cuts in Hearing (31m)
• Roche’s Genentech Fails to Win Adcomm Backing for Columvi Expansion (55m)
• Pfizer’s $6B China Deal, Drug Pricing and FDA’s New COVID Vaccine Plan (3h)
• The Top 5 Most Active Corporate VCs in Pharma (7h)
• Evolving Market Pressures Force Biopharma Companies to Cut Assets Early (8h)
• FDA’s New Risk-Based Approach to COVID-19 Vaccines Aims to Ease ‘Public Distrust’: Makary, Prasad (17h)
• New Details From Trump’s Drug Pricing Effort Put Branded Drugs in the Crosshairs (22h)
• CRISPR Success in Single Baby Highlights Rare Disease 'Crisis' (22h)
• Pfizer’s China Deal Worth up to $6B Eclipses Peers in a Frenzied Market (22h)
• Prime Cuts 25% of Staff, Deprioritizes CGD Programs (22h)

Bio IT World

• Innovative Practices Winner: Chromatography Data Management (8h)
• Regeneron Acquires 23andMe for $256 Million (1d)
• Trends from the Trenches: Data, Discovery, Politics (6d)
• Sweden's PROMISE Initiative: Bridging Research and Healthcare Through Multi-Omics (1w)
• CFDE Unites Data Enthusiasts During Hackathon before Kick-Off of Bio-IT World Conference (1w)
• MiLabs Launches Platforma: Bridging the Gap Between Biology and Bioinformatics (2w)
• First-of-its-Kind AI Tool Reveals the ‘Social Network’ of Cancer Cells (2w)
• Illumina, Ovation Release GLP-1 Patient Dataset (2w)
• Illumina, Tempus AI Collaboration, CN Bio, Pharmaron Partnership, More (3w)
• PacBio Licenses New Methylation Tech for HiFi Sequencing, Will Deliver to Revio, Vega Systems (3w)

• We’re reading about Trump’s drug-pricing plan, a Moderna change of plans, and more (13m)
• Risk scores accurately predicted heart attacks, study finds. With CT scans, they did even better (4h)
• Biden’s diagnosis highlights little-noticed rise in late-stage prostate cancers (4h)
• How photography helped heal a couple in the aftermath of cancer (4h)
• A husband and wife photographed each other during her cancer journey. Here is what they learned (4h)
• Proposed changes to the Public Service Loan Forgiveness program would be devastating to new physicians (4h)
• Three big ideas to actually ‘Make America Healthy Again’ (4h)
• Blunt Rochester presses RFK Jr. on CDC acting director (14h)
• New FDA framework on Covid vaccines leaves pediatricians confused and concerned (15h)
• RFK Jr. meets with health tech startups, most backed by Andreessen Horowitz (15h)

• Valinor Discovery Launches to Simulate Drug Efficacy in Virtual Patients (1d)
• Dutch Startup CryoCloud Lands €2M to Automate Cryo-EM for Drug Discovery (1d)
• Kvantify Taps Gefion AI Supercomputer to Scale Quantum Chemistry Simulations for Drug Discovery (1d)
• Eligo Bioscience Gets $5M Grant to Advance Gene-Editing Skin Therapy Using Bacteria (1d)
• Absci Doses First Participants in Phase 1 Trial of AI-Designed Antibody for IBD (1d)
• Medable Updates Digital Platform With Oncology-Focused Tools Ahead of ASCO 2025 (1d)
• Researchers Use Terahertz Imaging for First-Ever 3D View of Cochlea Without Surgery (1d)
• CRISPR Therapy Saves Infant With Rare Genetic Disorder (1d)
• Oracle Rebuilds Its EHR Infrastructure to Support AI-Native Workflows (1d)
• Regeneron Acquires 23andMe Assets for $256M to Expand Consumer Genomics and Data-Driven Drug Discovery (1d)

• Gene therapy for skin diseases: A field still finding its footing (5h)
• Seven lung cancer companies advancing new treatments in 2025 (1d)
• Will Europe become the new home for US researchers affected by policy shifts? (2d)
• Nine promising small molecule drug discovery companies to look out for in 2025 (5d)
• Fighting mucopolysaccharidosis type I, a rare disease, by reprogramming B-cells (5d)
• Expert tips to choose the right CDMO for your biotech company (6d)
• The stem cell race for Parkinson’s disease: Recent studies show significant promise (1w)
• Nine biotech companies in Montreal to keep an eye on in 2025 (1w)
• Cracking the code: Delivering biotherapeutics successfully across EMEA (1w)
• Pharma giants pull back on AAV research: what’s next for the gene therapy space? (1w)

• Potential ALS Mitochondrial Target Identified with CRISPR, scRNA-seq (1h)
• Oligo Factory’s Low-Scale Synthesis Expands Access to Small, GMP-Ready Custom Nucleotides (1h)
• Rapid Method for Cell Density Measurement Could Help Predict Tumor Response to Treatment (15h)
• ASGCT 2025: Gates Foundation “Doubling Down” on HIV Cure (23h)
• Scratch That? De Novo Antibody Design Enters the AI Drug Discovery Toolbox (1d)
• Donor Heart Damage From Cold Storage May Be Prevented by Diuretic (1d)
• The News from New Orleans: GEN‘s Takeaways from ASGCT (1d)
• CellProthera Selects CELLforCURE by SEQENS for Phase III GMP Manufacturing (1d)
• Prime Medicine Chops 25% of Workforce, Pivots Pipeline as CEO Quits (1d)
• Why the Right Launch Strategy Can Get Biopharma from Clinical Breakthroughs to Commercial Blockbusters (1d)

• Sixteen Years With Leukemia Taught Me to Savor Life (18m)
• Finding Meaning After an Acute Myeloid Leukemia Diagnosis (16h)
• Early Arterial Thrombosis May Signal Future Cancer Risk (17h)
• What are the Long-Term Side Effects of Proton Therapy in Prostate Cancer? (18h)
• The Unnamed Nurse who Saved My Life During Breast Cancer (20h)
• Acoustic Cluster Therapy Shows Benefit in Colorectal Liver Metastases (21h)
• Prostate Cancer Treatment Options: Common Questions in Focal Therapy, Surgery (22h)
• With Cancer in Remission, What Is the New Normal for Patients? (1d)
• Younger Patients With Lung Cancer Often Have Targetable Biomarkers (1d)
• Facing Cancer as an AYA and Navigating Fertility Preservation Choices (1d)

Contract Pharma*

• Regeneron in Deal to Acquire 23andMe for $256M (19h)
• Astoriom Expands Sample Stability Storage Services (20h)
• Fresenius Kabi Introduces Epinephrine Injection 30 mg per 30 mL Multi-Dose Vials (20h)
• NextCell, Fujifilm Irvine Scientific Enter Strategic Pact (20h)
• CellProthera Selects CELLforCURE by SEQENS for Phase 3 GMP Manufacturing (22h)
• CS Analytical Laboratory Opens Package Distribution Testing Service Expansion (22h)
• Shift Bioscience Announces Board and Advisor Appointments (23h)
• Zealand Pharma Appoints Chief Development Officer (1d)
• GC Biopharma Partners with Körber to Implement MES (2d)
• Cellino’s iPSC Manufacturing Technology Receives FDA AMT Designation (2d)

• Ionis shares phase 3 results for olezarsen in moderate hypertriglyceridaemia (2h)
• FDA approves Amneal’s self-administered migraine drug Brekiya (1d)
• MHRA approves guselkumab for Crohn’s disease and ulcerative colitis (2d)
• Massalia Therapeutics launches to advance novel treatments for complex conditions (2d)
• AviadoBio opens UK trial for FTD gene therapy (6d)
• Herantis Pharma doses final cohort in phase 1b trial of HER-096 for Parkinson’s disease (1w)
• Kaerus Bioscience secures orphan drug designation for fragile x syndrome treatment (1w)
• Rein Therapeutics initiates renew phase 2 trial for IPF treatment (1w)
• Apiary invests in life sciences marketing specialist performance-io (1w)
• Amgen’s Tepezza granted marketing authorisation in the UK (2w)

• How a New PE-Backed RCM Company Plans to Fix the ‘Transactional Bowels of US Healthcare’ (9h)
• 3 Health Investors Share Their Most Controversial Industry Takes (9h)
• How a Tiny Federal Agency Supports Innovation & Competitiveness in the Scientific Community (10h)
• Payments Simplified: The 4 Key Features of Modern Healthcare Payment Platforms (23h)
• The Changing Landscape of Ransomware: Why Healthcare Organizations Are Paying Less (23h)
• The Role of Consultants in Tackling Healthcare Expenses (1d)
• 23andMe Bankruptcy Auction Win Adds Big Piece to Regeneron’s Gene-Based Drug R&D Efforts (1d)
• How One Company Aims to Save Lives with Its Smartwatch (1d)
• How One Startup Is Standing Out in the Crowded AI Scribe Market (1d)
• Why Agentic AI Is Not Quite Ready for Primetime in Healthcare (2d)

• Editorial: Venture capital still likes cleantech (20h)
• A guide to navigating AI chemistry hype (21h)
• Federal policy changes spell turmoil for biopharma (23h)
• Global pandemic treaty nears adoption, but key obstacle remains (1d)
• ACS puts the spotlight on chemical technical professionals (1d)
• Comment: Why attend ACS Fall 2025? (1d)
• Mercury emissions are falling (2d)
• Flu virus transcription caught in the act (4d)
• AI start-up raises $11 million to make drug formulations better (4d)
• A baby gets the world’s first personalized CRISPR therapy (4d)

The Pharma Letter*

• Juvenescence raises $76 million in first-close of Series B-1 round (1h)
• SparX teams with Mitsubishi Tanabe on novel ADC project (2h)
• PureTech’s deupirfenidone shows strong and durable efficacy (2h)
• Tourmaline shares waver as investors mull mid-stage pacibekitug data (2h)
• Tubulis achieves key milestone in BMS deal (2h)
• J&J presents long-term Opsynvi findings at ATS (3h)
• SK bio wins Korean Supreme Court backing in Pfizer patent battle (3h)
• FDA advisers back Darzalex, raise concerns over Columvi trial (3h)
• SK wins Korean Supreme Court backing in Pfizer patent battle (3h)
• MHRA launches new consultation on real-world clinical trials data (4h)

• Maintenance Selinexor Extends PFS in TP53 Wild-Type Endometrial Cancer (18m)
• CABINET Trial: Results (1h)
• CYTO-PV Trial Insights: Optimizing Hematocrit Targets and Thrombosis Prevention in Polycythemia Vera (1h)
• CABINET Trial: Study Design and Patient Population (1h)
• Comparative Analysis of Major Polycythemia Vera Clinical Trials: PROUD-PV, MAJIC-PV, RESPONSE, and CYTO-PV (1h)
• CAR T Toxicity Differences Seen in Transplant-Ineligible LBCL (16h)
• ODAC Votes Daratumumab Benefits Smoldering MM (16h)
• Unmet Needs and Therapy Modifications Relevant in the CRC Landscape (18h)
• Myeloma Research Sees Transformation Following ODAC Support For MRD End Point (19h)
• The Importance of Global Collaboration in Oncology: Li's View (20h)

• Fruergaard's exit leaves many questions: Speculation about cause, power struggle and US problems (37m)
• US health clinic Calibrate changes management (1h)
• Demant surpasses Novo Nordisk on list of Europe's best employers (2h)
• Genmab drug gets support from US authorities (4h)
• Trump shows first figures on decreed drug price cuts (5h)
• Zealand Pharma appoints new development chief with experience from Novo Nordisk and FDA (23h)
• China will provide extra support to WHO (1d)
• Regeneron acquires US biotech firm (1d)
• Over 100 countries vote for global pandemic agreement (1d)
• Pfizer licenses 3SBio cancer drug for record USD 1.25bn (1d)

• Autoimmune Disease, Transformed? (17h)
• Lose Your Crystalline Form and Go Amorphous (1d)
• Alzheimer's Update: Infectious Agents and Gamma-Secretase Too (5d)
• Obesity Without Metabolic Dysfunction? (6d)
• New Cell Therapy For Resistant Hodgkins Patients (1w)
• Escape From the Lysosome (1w)
• Heavy Water in Your NMR Experiments, And Elsewhere (2w)
• GIPR: Agonists and Antagonists Do the Same Thing, But How (2w)
• Mutant Proteins Classified (2w)
• The Continuing Crisis, Part XIV: The Trumpist Worldview (2w)

• US imposes limits on COVID-19 boosters and new jabs (10m)
• UK to start "world first" gonorrhoea vaccine programme (1h)
• Beckley's psychedelic med inches forward in depression (2h)
• UK trumpets £1bn investment plan from BioNTech (3h)
• First details of Trump's most favoured nation plan emerge (4h)
• O'Shaughnessy says UK clinical trials sector is on the mend (1d)
• Imec showcases ingestible sensor for gut studies (1d)
• UK's long-term R&D investment policy welcomed (1d)
• Pfizer snaps up PD-1/VEGF drug from China's 3SBio (1d)
• Regeneron swoops on genetic testing firm 23andMe (2d)

• BioNTech commits to up to £1 billion investment in the UK (1h)
• Weight loss with muscle preservation for novel small molecule (3h)
• Whitepaper: Transforming cardiac safety testing (3h)
• VOLTA Scanner illuminates cardiac safety testing (3h)
• Cell therapy (beyond CAR-T) and opportunities for new medicines (5h)
• Meet the Researcher: Duncan McHale, Persica Pharmaceuticals (5h)
• Webinar: Where are the developments in cancer research? (5h)
• We need international partnerships to get new cancer drugs into the clinic (22h)
• Gene-based vaccine shows promise in early-stage trial (1d)
• First patient receives personalised CRISPR gene editing therapy (1d)

Google News Biotech

• Lilly’s former small molecule head makes the leap to a rising biotech in obesity - Pharma Voice (44m)
• RBC downgrades Sartorius Stedim Biotech to “sector perform,” sets €240 target - Investing.com (56m)
• Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101 - The Manila Times (57m)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - ACCESS Newswire (1h)
• Northway Biotech Enters Manufacturing Agreement With Kaida BioPharma for Lead Oncology Program KAD101 - Morningstar (1h)
• Kaida BioPharma Announces New Partnership with Northway Biotech for the Manufacturing of KAD101 - GlobeNewswire (1h)
• German biotech firm SenseUP closes €2.4M Seed round - Silicon Canals (1h)
• Purple Biotech Reports First Quarter 2025 Financial Results - The Manila Times (1h)
• Purple Biotech Reports First Quarter 2025 Financial Results - Yahoo Finance (2h)
• Bharat Biotech’s oral cholera vaccine Hillchol proves effective on year-old infants to adults - CNBC TV18 (2h)